Luz Alonso, MD
Internal Medicine · Apopka, FLNPI 1376524223
Payments from drug & device makers
Across 400 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$666
- Boehringer Ingelheim$546
- Abbott$269
- Pfizer$257
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,75398%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 107 | $2,209 |
| AstraZeneca | 75 | $1,464 |
| Lilly USA, LLC | 40 | $666 |
| Boehringer Ingelheim | 30 | $546 |
| Abbott | 14 | $269 |
| Pfizer | 12 | $257 |
| AbbVie(2 entities) | 13 | $243 |
| Astellas Pharma US Inc | 8 | $241 |
| Exact Sciences | 10 | $207 |
| Sanofi-aventis U.S. LLC | 9 | $186 |
| Bayer | 8 | $181 |
| Medtronic(2 entities) | 2 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $150 |
| Amgen | 8 | $144 |
| Amneal Pharmaceuticals LLC | 9 | $138 |
| GSK | 8 | $138 |
| Dexcom, Inc. | 1 | $122 |
| Merck | 9 | $116 |
| Amarin Pharma, Inc. | 6 | $98 |
| Shield Therapeutics Inc | 5 | $85 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Johnson & Johnson | 2 | $40 |
| Hologic Sales And Service, LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Grifols USA, LLC | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$219
- IN.PACT Admiral$158
- DEXCOM G7 GSS (161)$122
- DEXCOM STELO GLUCOSE BIOSENSOR$122
- FARXIGA$105
- SYMBICORT$105
How this compares
$7,887 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $71,055 |
| JanuviaSitagliptin Phosphate | 21 | $32,350 |
| RybelsusSemaglutide | 21 | $32,033 |
| JardianceEmpagliflozin | 26 | $28,528 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $22,150 |
| EliquisApixaban | 16 | $20,845 |
| MounjaroTirzepatide | 12 | $18,807 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $17,076 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $12,199 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $11,506 |
| SynthroidLevothyroxine Sodium | 48 | $4,202 |
| Novolog FlexpenInsulin Aspart | 13 | $3,539 |
| Rosuvastatin Calcium | 200 | $2,377 |
| Celecoxib | 13 | $2,265 |
| Gabapentin | 104 | $1,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,209 | $103,08869 claims |
| MerckJanuvia, Janumet | $116 | $43,85641 claims |
| Boehringer IngelheimJardiance | $546 | $28,52826 claims |
| PfizerEliquis | $257 | $20,84516 claims |
| Lilly USA, LLCMounjaro | $666 | $18,80712 claims |
| GSKTrelegy Ellipta | $138 | $17,07615 claims |
| AbbVieSynthroid | $243 | $4,20248 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $138 | $1,920190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Apopka
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.